**Table S1.** The clinical characteristics of cases and controls included in the study.

|  |  |  |  |
| --- | --- | --- | --- |
| Characteristics | Cases | Controls | *P* |
| TB cases and controls |  |  |  |
| All | n = 1032 | n = 1008 |  |
| Age, mean in years ±SD | 39.3 ± 19.3 | 45.2 ± 24.2 | 1.10 × 10-9 |
| < 46, n (%) | 441 (43.8) | 660 (64.0) | 5.5 × 10-20 |
| ≥ 46, n (%) | 567 (56.2) | 372 (36.0) |  |
| Gender |  |  |  |
| Female, n (%) | 474 (47.0) | 427 (41.4) | 0.010 |
| Male, n (%) | 534 (53.0) | 605 (58.6) |  |
| Used in methylation analysis | n = 18 | n = 18 |  |
| Age, mean in years ±SD | 39.6 ± 17.4 | 40.8 ± 22.3 | N.S. |
| rs3755276 C/C | 40.8 ± 20.3 | 40.3 ± 24.1 | N.S. |
| rs3755276 C/T | 40.5 ± 18.7 | 40.3 ± 18.2 | N.S. |
| rs3755276 T/T | 37.5 ± 15.9 | 41.8 ± 27.9 | N.S. |
| Gender, number of male / female | 13 / 5 | 13 / 5 | N.S. |
| rs3755276 C/C | 4 / 2 | 4 / 2 | N.S. |
| rs3755276 C/T | 4 / 2 | 5 / 1 | N.S. |
| rs3755276 T/T | 5 / 1 | 4 / 2 | N.S. |
|  |  |  |  |
| Additional healthy controls |  |  |  |
| All |  | n = 95 |  |
| Age, mean in years ±SD |  | 52.1 ± 5.6 |  |
| rs3755276 C/C |  | 51.8 ± 5.2 | N.S. |
| rs3755276 C/T |  | 53.3 ± 6.6 |  |
| rs3755276 T/T |  | 52.3 ± 6.4 |  |
| Gender, number of male / female |  | 51 / 44 |  |
| rs3755276 C/C |  | 36 / 32 | N.S. |
| rs3755276 C/T |  | 13 / 11 |  |
| rs3755276 T/T |  | 2 / 1 |  |
| Used in methylation analysis |  | n = 30 |  |
| Age, mean in years ±SD |  | 53.6 ± 6.0 |  |
| rs3755276 C/C |  | 53.2 ± 5.8 | N.S. |
| rs3755276 C/T |  | 54.7 ± 6.7 |  |
| rs3755276 T/T |  | 52.3 ± 6.4 |  |
| Gender, number of male / female |  | 16 / 14 |  |
| rs3755276 C/C |  | 9 / 8 | N.S. |
| rs3755276 C/T |  | 5 / 5 |  |
| rs3755276 T/T |  | 2 / 1 |  |

N.S., not significant. Cases are patients with tuberculosis, while 1,008 controls are those with non-tuberculous diseases, including cardiovascular diseases (26.4%), bone diseases (19.5%), neurological or psychiatric conditions (17.5%), acute upper respiratory infections (14.3%), kidney diseases (8.1%), gastrointestinal or hepatobiliary system complaints (6.2%), and other diseases of blood, urine, lymph, eye, or skin (8.0%). For controls used in methylation analysis, six C/C carriers had cardiovascular (n = 2), bone (n = 1), neurological (n = 1), respiratory (n= 1), or skin (n = 1) diseases; six C/T carriers had cardiovascular (n = 1), bone (n = 2), neurological (n = 2), or blood (n = 1) diseases; six T/T carriers had cardiovascular (n = 2), bone (n = 2), gastrointestinal (n = 1), or skin (n = 1) diseases. Comparisons of sex and age distributions between cases and controls were performed by use of the *χ2* test. Differences of mean age between cases and controls were analyzed by use of an unpaired *t* test. In the additional healthy controls, two-way ANOVA was used to compare the mean age among the three genotypic groups. Comparisons of sex distribution among the three genotypic groups were performed by use of the *χ2* test for 2 × 3 contingency tables.